Scarica l'app Stockscreener
4.40
0.92%
0.04
Dopo l'orario di chiusura:
4.39
-0.01
-0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition - ts2.tech
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance
Is Recursion Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Market Mood & High Accuracy Trade Alerts - Bölüm Sonu Canavarı
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo! Finance Canada
Aug Retail: Will Recursion Pharmaceuticals Inc stock gain from lower inflationMarket Volume Summary & Daily Profit Maximizing Trade Tips - moha.gov.vn
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Insider Monkey
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech
Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
Is Recursion Pharmaceuticals Inc. stock a safe buy before earningsJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - Улправда
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech
Published on: 2025-12-19 22:42:25 - Улправда
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Will Recursion Pharmaceuticals Inc. stock benefit from green energy trends2025 Trading Recap & AI Based Trade Execution Alerts - DonanımHaber
Cathie Wood’s ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals - Investing.com
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsidePortfolio Profit Report & Daily Chart Pattern Signals - DonanımHaber
Is Recursion Pharmaceuticals a Meme Stock? - MSN
How Recursion Pharmaceuticals Inc. stock compares to growth peersTrade Performance Summary & Weekly Market Pulse Updates - DonanımHaber
How Recursion Pharmaceuticals Inc. stock compares to market leadersPortfolio Risk Summary & Low Risk Investment Opportunities - DonanımHaber
What hedge fund activity signals for Recursion Pharmaceuticals Inc. stock2025 Sector Review & Smart Swing Trading Alerts - Улправда
Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN
RXRX Stock: Analyzing the Dive and Its Impact - StocksToTrade
RXRX Stock Insight: Unraveling Latest Developments - timothysykes.com
Update Report: Is Recursion Pharmaceuticals Inc stock overvalued by current metricsCEO Change & Precise Buy Zone Tips - moha.gov.vn
Recursion Pharmaceuticals: Upgrading To BuyMy Most Surprising Call Of 2025 (RXRX) - Seeking Alpha
RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes
Is Recursion Pharmaceuticals Stock Attractive? - Trefis
Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet - Finviz
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next - ts2.tech
Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet - Insider Monkey
What Recursion Pharmaceuticals (RXRX)'s FAP Trial Win And AI Platform Validation Means For Shareholders - simplywall.st
U.S. stock market movement | AI healthcare concept stock Recursion continues to rise 3.8% in pre-market trading, Morgan Stanley raises rating + Cathie Wood increases position. - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX) - The Globe and Mail
JPMorgan has upgraded Recursion (RXRX.US) to an 'Overweight' rating, with its core pipeline candidate REC-4881 expected to become a blockbuster drug. - 富途牛牛
Backed by Nvidia, Recursion Soars 11% Following Bullish Analyst Call and Clinical Trial Update - NAI500
Why Recursion Pharmaceuticals stock vaulted 11% higher on Wednesday - MSN
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - Nasdaq
CFO Taylor Surrenders 7,057 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Stock Traders Buy Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks making the biggest moves today - MSN
Recursion Pharmaceuticals: Is Now the Time to Invest? - StocksToTrade
Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade - marketscreener.com
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why - Benzinga
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today - Stocktwits
10 Best NASDAQ Stocks Under $10 to Buy - Insider Monkey
Recursion Pharmaceuticals Triumphs in FAP Trial, Boosting Investor Confidence - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral' - marketscreener.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded to Overweight at JPMorgan Chase & Co. - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan - TipRanks
0.36%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):